Last update March 29, 2022
Very Low Risk
Desogestrel is a progestogen with a structure similar to levonorgestrel that is used as a contraceptive, alone or associated with an estrogen such as ethinyl estradiol. It is metabolized in the body to etonogestrel. Daily oral administration.
It is excreted in breast milk in clinically insignificant amounts (Bjarnadóttir 2001), with no harmful effects on breastfed infants from treated mother reported, except for two cases of transient gynecomastia (Bjarnadóttir 2001) and a case of scrotal hypertrichosis in a 4-month-old infant whose mother had also received treatment with another progestogen during pregnancy. (Janus 2013)
Desogestrel does not change the quantity or composition of milk, nor the growth and development of children followed up to 2.5 years. (Dutta 2013, Bjarnadóttir 2001)
During lactation progestin-only contraceptives are preferable to those combined with estrogen and, in this case, those with a lower dose of estrogen. (CDC 2016, WHO/OMS 2015, Altshuler 2015, Berens 2015, CLM 2012, Moretti 2000)
For the first 4-6 weeks postpartum, non-hormonal methods are the first choice, followed by IUDs and progestogen implants. (Berens 2015, Mwalwanda 2013, Rowe 2013, CLM 2012)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM